Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.

Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ.

J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19.

PMID:
31537613
2.

Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.

Bennett MJ, Wu Y, Boloor A, Matuszkiewicz J, O'Connell SM, Shi L, Stansfield RK, Del Rosario JR, Veal JM, Hosfield DJ, Xu J, Kaldor SW, Stafford JA, Betancort JM.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1811-1816. doi: 10.1016/j.bmcl.2018.04.016. Epub 2018 Apr 10.

PMID:
29657099
3.

Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.

Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB.

ACS Med Chem Lett. 2017 Jul 27;8(8):869-874. doi: 10.1021/acsmedchemlett.7b00220. eCollection 2017 Aug 10.

4.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.

Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P.

Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24.

5.

Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells.

Murai S, Matuszkiewicz J, Okuzono Y, Miya H, DE Jong R.

Anticancer Res. 2017 Feb;37(2):437-444.

PMID:
28179288
6.

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).

Lam B, Arikawa Y, Cramlett J, Dong Q, de Jong R, Feher V, Grimshaw CE, Farrell PJ, Hoffman ID, Jennings A, Jones B, Matuszkiewicz J, Miura J, Miyake H, Natala SR, Shi L, Takahashi M, Taylor E, Wyrick C, Yano J, Zalevsky J, Nie Z.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. doi: 10.1016/j.bmcl.2016.10.087. Epub 2016 Nov 2.

PMID:
27839918
7.

Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.

Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, Elliott S, Fabrey R, Lee B, Halkowycz P, Sang B, Ishino S, Nomura T, Teratani M, Ohta Y, Grimshaw C, Paraselli B, Satou T, de Jong R.

Mol Cancer Ther. 2013 Apr;12(4):460-70. doi: 10.1158/1535-7163.MCT-12-0657. Epub 2013 Jan 28.

8.

[Treatment of lupus nephropathy with large doses of steroids. Personal experience].

Matuszkiewicz J, Wardyn K, Imiela J, Siciński A.

Pol Arch Med Wewn. 1982 Nov;68(5):319-28. Polish. No abstract available.

PMID:
7182833
9.

[A new synthetic diet for acute and chronic advanced renal insufficiency].

Poleć R, Kurkus J, Matuszkiewicz J.

Z Gesamte Inn Med. 1979 Nov 1;34(21):suppl 292-3. German.

PMID:
550612
10.

[Clinical usefulness of ultrafiltration without dialysis in the process of hemodialysis treatment of terminal renal failure].

Fałda Z, Imiela J, Siciński A, Matuszkiewicz J.

Pol Arch Med Wewn. 1979 Apr;61(4):283-9. Polish. No abstract available.

PMID:
471803
11.

[A trial to apply albothyl in treating diseases of the oral mucosa. (Preliminary report)].

Matuszkiewicz J.

Czas Stomatol. 1967 Jan;20(1):25-6. Polish. No abstract available.

PMID:
5335246
12.

[A case of internal resorption of a tooth undetected at the initial stage].

Matuszkiewicz J.

Czas Stomatol. 1966 Feb;19(2):173-7. Polish. No abstract available.

PMID:
5219997

Supplemental Content

Loading ...
Support Center